578 related articles for article (PubMed ID: 10318961)
1. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.
Zimmer A; Zimmer AM; Hohmann AG; Herkenham M; Bonner TI
Proc Natl Acad Sci U S A; 1999 May; 96(10):5780-5. PubMed ID: 10318961
[TBL] [Abstract][Full Text] [Related]
2. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
[TBL] [Abstract][Full Text] [Related]
3. Behavioral effects of cannabinoid agents in animals.
Chaperon F; Thiébot MH
Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
[TBL] [Abstract][Full Text] [Related]
4. Neurobehavioral effects of delta 9-THC and cannabinoid (CB1) receptor gene expression in mice.
Onaivi ES; Chakrabarti A; Gwebu ET; Chaudhuri G
Behav Brain Res; 1995 Dec; 72(1-2):115-25. PubMed ID: 8788864
[TBL] [Abstract][Full Text] [Related]
5. Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse.
Azad SC; Marsicano G; Eberlein I; Putzke J; Zieglgänsberger W; Spanagel R; Lutz B
Eur J Neurosci; 2001 Feb; 13(3):561-8. PubMed ID: 11168564
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF
Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483
[TBL] [Abstract][Full Text] [Related]
7. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
8. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
9. Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice.
Monory K; Blaudzun H; Massa F; Kaiser N; Lemberger T; Schütz G; Wotjak CT; Lutz B; Marsicano G
PLoS Biol; 2007 Oct; 5(10):e269. PubMed ID: 17927447
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
Romero J; Garcia-Palomero E; Castro JG; Garcia-Gil L; Ramos JA; Fernandez-Ruiz JJ
Brain Res Mol Brain Res; 1997 Jun; 46(1-2):100-8. PubMed ID: 9191083
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor.
Buckley NE; McCoy KL; Mezey E; Bonner T; Zimmer A; Felder CC; Glass M; Zimmer A
Eur J Pharmacol; 2000 May; 396(2-3):141-9. PubMed ID: 10822068
[TBL] [Abstract][Full Text] [Related]
12. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.
Ledent C; Valverde O; Cossu G; Petitet F; Aubert JF; Beslot F; Böhme GA; Imperato A; Pedrazzini T; Roques BP; Vassart G; Fratta W; Parmentier M
Science; 1999 Jan; 283(5400):401-4. PubMed ID: 9888857
[TBL] [Abstract][Full Text] [Related]
13. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
Yamaguchi T; Hagiwara Y; Tanaka H; Sugiura T; Waku K; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2001 Aug; 909(1-2):121-6. PubMed ID: 11478928
[TBL] [Abstract][Full Text] [Related]
14. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
15. New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application.
Fujiwara M; Egashira N
J Pharmacol Sci; 2004 Dec; 96(4):362-6. PubMed ID: 15599103
[TBL] [Abstract][Full Text] [Related]
16. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
17. Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment.
Wu X; French ED
Neuropharmacology; 2000 Jan; 39(3):391-8. PubMed ID: 10698005
[TBL] [Abstract][Full Text] [Related]
18. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
[TBL] [Abstract][Full Text] [Related]
19. The pharmacological activity of inhalation exposure to marijuana smoke in mice.
Lichtman AH; Poklis JL; Poklis A; Wilson DM; Martin BR
Drug Alcohol Depend; 2001 Jul; 63(2):107-16. PubMed ID: 11376914
[TBL] [Abstract][Full Text] [Related]
20. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
